Skip to search formSkip to main contentSkip to account menu

capecitabine/cisplatin/epirubicin/matuzumab

Known as: CAPE/CDDP/EMD 72000/EPI 
National Institutes of Health

Related topics

Related topics

4 relations
CisplatinEpirubicin Hydrochloridecapecitabinematuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Signifikante EGF Rezeptor Inhibition und anhaltende antineoplastische Wirkung durch Matuzumab Kurzzeittherapie (EMD72000) im experimentellen Pankreaskarzinom Matuzumab short term therapy (EMD72000…
Pancreatic cancer continues to be a major unsolved health problem with a median overall survival of 4-6 month. Standard… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)